anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
* Hydrocodone bitartrate extended-release tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of extended-release/long-acting opioids and how to mitigate the associated risks.
  * Daily doses of hydrocodone bitartrate extended-release tablets greater than or equal to 80 mg are only for use in patients in whom tolerance to an opioid of comparable potency has been established. Patients who are opioid tolerant are those receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.
  * Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals [see Warnings and Precautions (5)]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of hydrocodone bitartrate extended-release tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. 
  * Initiate the dosing regimen for each patient individually, taking into account the patient's underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)]. 
  * Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with hydrocodone bitartrate extended-release tablets. Consider this risk when selecting an initial dose and when making dose adjustments [see Warnings and Precautions (5.2)].
  * Instruct patients to swallow hydrocodone bitartrate extended-release tablets whole, one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth. Instruct patients not to pre-soak, lick, or otherwise wet the tablet prior to placing in the mouth [see Warnings and Precautions (5.13)]. Crushing, chewing, or dissolving hydrocodone bitartrate extended-release tablets will result in uncontrolled delivery of hydrocodone and can lead to overdose or death [see Warnings and Precautions (5.1)].
  * Hydrocodone bitartrate extended-release tablets are administered orally once daily (every 24 hours). Multiple tablets of lower dose strengths that provide the desired total daily dose can be taken as a once daily dose.
Patients would be administered Enoxaparine (60 mg/SC/BID)in first day, after dicontinuing Enoxaparin in second day, Rivoroxaban 20 mg per day will use. .it would be given once a day.The total duration of Rivoroxaban would be 3 months.
AIMS: Abdominal aortic aneurysm (AAA) is a highly lethal disease with progressive dilatation of the abdominal aorta accompanied by degradation and remodelling of the vessel wall due to chronic inflammation. Platelets play an important role in cardiovascular diseases, but their role in AAA is poorly understood.
METHODS AND RESULTS: The present study revealed that platelets play a crucial role in promoting AAA through modulation of inflammation and degradation of the extracellular matrix (ECM). They are responsible for the up-regulation of SPP1 (osteopontin, OPN) gene expression in macrophages and aortic tissue, which triggers inflammation and remodelling and also platelet adhesion and migration into the abdominal aortic wall and the intraluminal thrombus (ILT). Further, enhanced platelet activation and pro-coagulant activity result in elevated gene expression of various cytokines, Mmp9 and Col1a1 in macrophages and Il-6 and Mmp9 in fibroblasts. Enhanced platelet activation and pro-coagulant activity were also detected in AAA patients. Further, we detected platelets and OPN in the vessel wall and in the ILT of patients who underwent open repair of AAA. Platelet depletion in experimental murine AAA reduced inflammation and ECM remodelling, with reduced elastin fragmentation and aortic diameter expansion. Of note, OPN co-localized with platelets, suggesting a potential role of OPN for the recruitment of platelets into the ILT and the aortic wall.
CONCLUSION: In conclusion, our data strongly support the potential relevance of anti-platelet therapy to reduce AAA progression and rupture in AAA patients.
Systems for use with a medical device for reducing medication errors are provided. In one aspect, a system includes a medical device that is configurable with operating limit parameters for providing medication to a patient, and a limiting system. The limiting system includes a memory that includes patient-specific information for the patient and a database includes acceptable operating parameters for providing the medication to the patient using the medical device, and a processor. The processor is configured to compare the acceptable operating parameters with the patient-specific information, and provide a modification of the operating limit parameters for providing the medication to the patient based on the comparison of the acceptable operating parameters with the patient-specific information. Methods and machine-readable media are also provided. Caregiver programs medical device- Establish communication link between medical device and control system Medical device communicates medication delivery information to control system Control system compares medication delivery information to medication guidelines database in view of patient-specific information 118 Medication delivery information outside Yes acceptable guidelines ? 120 No Provide confirmation message and/or send signal to medical device Allow/Begin medication delivery 124:: S Alert Provide modified delivery information based on medication guidelines database in view of patient-specific information Yes 128 Modified No delivery information accepted
Senescent cells accumulate in various organs with ageing, and its accumulation induces chronic inflammation and age-related physiological dysfunctions. Several remodelling of intracellular environments have been identified in senescent cells, including enlargement of cell/nuclear size and intracellular acidification. Although these alterations of intracellular environments were reported to be involved in the unique characteristics of senescent cells, the contribution of intracellular acidification to senescence-associated cellular phenotypes is poorly understood. Here, we identified that the upregulation of TXNIP and its paralog ARRDC4 as a hallmark of intracellular acidification in addition to KGA-type GLS1. These genes were also upregulated in response to senescence-associated intracellular acidification. Neutralization of the intracellular acidic environment ameliorated not only senescence-related upregulation of TXNIP, ARRDC4 and KGA but also inflammation-related genes, possibly through suppression of PDK-dependent anaerobic glycolysis. Furthermore, we found that expression of the intracellular acidification-induced genes, TXNIP and ARRDC4, correlated with inflammatory gene expression in heterogeneous senescent cell population in vitro and even in vivo, implying that the contribution of intracellular pH to senescence-associated cellular features, such as SASP.
Intestinal adaptation does not necessarily recover absorptive capacity in short bowel syndrome (SBS), sometimes resulting in intestinal failure-associated liver disease (IFALD). Additionally, its therapeutic options remain limited. Polyamines (spermidine and spermine) are known as one of the autophagy inducers and play important roles in promoting the weaning process; however, their impact on intestinal adaptation is unknown. The aim of this study was to investigate the impact of polyamines ingestion on adaptation and hepatic lipid metabolism in SBS. We performed resection of two-thirds of the small intestine in male Lewis rats as an SBS model. They were allocated into three groups and fed different polyamine content diets (0%, 0.01%, 0.1%) for 30 days. Polyamines were confirmed to distribute to remnant intestine, whole blood, and liver. Villous height and number of Ki-67-positive cells in the crypt area increased with the high polyamine diet. Polyamines increased secretory IgA and mucin content in feces, and enhanced tissue Claudin-3 expression. In contrast, polyamines augmented albumin synthesis, mitochondrial DNA copy number, and ATP storage in the liver. Moreover, polyamines promoted autophagy flux and activated AMP-activated protein kinase with suppression of lipogenic gene expression. Polyamines ingestion may provide a new therapeutic option for SBS with IFALD.
Rice blast, caused by the fungus Magnaporthe oryzae (syn. Pyricularia oryzae), is a major problem in rice cultivation and ranks among the most severe fungal diseases. Cloning and identifying resistance genes in rice, coupled with a comprehensive examination of the interaction between M. oryzae and rice, may provide insights into the mechanisms of rice disease resistance and facilitate the creation of new rice varieties with improved germplasm. These efforts are essential for protecting food security. This review examines the discovery of genes that confer resistance or susceptiblity to M. oryzae in rice over the last decade. It also discusses how knowledge of molecular mechanisms has been used in rice breeding and outlines key strategies for creating rice varieties resistant to this disease. The strategies discussed include gene pyramiding, molecular design breeding, editing susceptibility genes, and increasing expression of resistance genes through pathogen challenge. We address the prospects and challenges in breeding for rice blast resistance, emphasizing the need to fully exploit germplasm resources, employ cutting-edge methods to identify new resistance genes, and develop innovative breeding cultivars. Additionally, we underscore the importance of understanding the molecular basis of rice blast resistance and developing novel cultivars with broad-spectrum disease resistance.
PROBLEM TO BE SOLVED: To obtain a new compound useful as a medicament such as a hypoglycemic agent or prophylactic/therapeutic agent for diabetes. SOLUTION: This new compound is a compound of formula I (R1 and R2 are each a lower alkyl or H; R3 is H, a lower alkyl or the like, R4 and R5 are each a lower alkoxy, lower alkoxycarbonyl or the like; R6 is OH, phenyl or the like; ring A is an aromatic ring or heterocyclic ring; Q is a single bond or phenylene which may be substituted with halogen(s) or the like; n is 1-6), pref. diethyl 4- N-[3-chloro-2-(N-methylcarbamoyl)(phenyl]sulfamoyl}- benzylphosphonate or the like.  The compound of formula I is obtained, for example, by treating a compound of formula II (R1a and R2a are each a lower alkyl; Q' is phenylene which may be substituted with halogen(s) or the like) (e.g. diethyl benzylphosphonate) with a compound of the formula X-SO3H (X is a halogen) (e.g. chlorosulfuric acid) followed by reaction of the resulting compound thus formed with a compound of formula III (e.g. 6-chloro-N- methylanthranilamide).
PURPOSE:A composition that contains, as an active ingredient, a raffinose ester of 14-20 carbon higher fatty acid, which dissolves triterpene alcohol ester of ferulic acid, thus showing stability as a cosmetic, causing no skin irritation, having antioxidative action and action to stimulate skin glands. CONSTITUTION:The objective composition contains, as an active ingredient, a raffinose ester of a higher fatty acid of 14-20 carbon atoms, which dissolves triterpene alcohol ester of ferulic acid, further cosmetic bases, auxiliary agents and other additives and is made into skin cosmetics such as cream, milk lotion, pack or lotion. The amount of the raffinose ester is preferably 2-4pts. in cream or milk lotion, 0.5-1pt. in mask and 0.1-0.2pt. in lotion. The higher fatty acid is mainly myristic acid and stearic acid and the triterpene alcohol ester of ferulic acid is preferably composed of esters of cycloeucalenol, cycloartenol; 2,4- methylene cycloartanol and cyclobranol.
Background and Objectives: In this study, we aimed to evaluate pain intensity in patients after pilonidal disease surgeries of varying extent using pressure algometry and the visual analog scale and to explore potential correlations between these methods. Materials and Methods: A total of 78 adult patients with symptomatic pilonidal cysts were enrolled in this study. The patients were divided into two groups based on the type of surgery assigned to each patient at the pre-hospital consultation: pit-picking surgery (n = 39) and radical excision (n = 39). The pain levels at the surgical site were assessed and compared using the visual analog scale (VAS) and pressure algometry the morning before surgery and the day after the operation. Results: There was no statistically significant difference (p > 0.05) in VAS measurement results between surgical groups when comparing pain intensity experienced by patients before, during, and after surgery. Notably, specific pressure algometry variables (pressure pain tolerance left 2.05 ± 1.46 compared to 1.42 ± 0.73 kg/cm2, p = 0.02; maximum pressure pain tolerance left 2.91 ± 1.33 compared to 2.32 ± 1.14 kg/cm2, p = 0.04; maximum pressure pain tolerance center 2.51 ± 1.07 compared to 1.91 ± 0.91 kg/cm2, p = 0.01; interval of pressure pain tolerance center 0.98 ± 0.62 compared to 0.59 ± 0.39 kg/cm2, p = 0.00) on the first postoperative day were significantly lower in the "pit-picking" group compared to the excision group. Furthermore, no statistically significant correlation was found between VAS and pressure algometry measurements either before surgery or on the first postoperative day. Conclusions: In the early postoperative period following pilonidal disease surgery of varying extents, pain measured with the VAS does not differ. In contrast, the pressure algometry method showed greater pain in the minimally invasive surgery cohort on the first postoperative day. However, further larger studies are needed to compare these pain assessment methods in reporting pain intensity experienced during patient movement.
<P>PROBLEM TO BE SOLVED: To obtain the direct target of Myc being a cell proliferation factor and a transcription factor and to provide a means for regulating a tissue-specific phenomenon of a eukaryote.  <P>SOLUTION: The nucleotide for regulating a tissue-specific phenomenon by Myc is derived from a TAF4b comprising a TATA box and a CGCGTG motif and/or a CACGTG motif positioned at its 1-50 bases upstream as an essential sequence. The vector comprises the nucleotide. The reporter plasmid comprises the nucleotide and a reporter gene. The transformant or the transgenic non-human animal is obtained by transduction of the vector or the reporter plasmid. The method for screening a cell proliferation regulator or a pregnancy regulator comprises using the reporter plasmid or the transformant.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Participants received body-weight stratified dosage of canakinumab treatment at 300 milligrams (mg) (for participants weighing more than 40 kilograms (kg)) and at 2 mg/kg (for participants weight less than or equal to 40 kg) subcutaneously every 4-8 weeks as per investigator discretion for a treatment period of 6 months. The first 3 Neonatal-Onset Multisystem Inflammatory Disease (NOMID) participants enrolled received a dose of 150 mg (\>40 kg) and 2 mg/kg for children \<40 kg. Since this dose was insufficient to fully control the symptoms of the disease the 300 mg / 4mg/kg dose was introduced by Protocol Amendment 2.
BACKGROUND: Frailty is increasing worldwide as the population ages. Physical activity is one component that has been shown to hinder and even reverse the process. The POSITIVE system (i.e., maintaining and imPrOving the intrinSIc capaciTy Involving primary care and caregiVErs) is a prevention program that consists of home-monitoring equipment and a communication platform to support the initial treatment of frailty symptoms in primary health care. The participants, older aged (+ 70) frail persons and those at risk for frailty, took part in the program that promoted physical activity at home for six months. The aim was to explore and describe older persons' experiences of participating in a new prevention program using the POSITIVE system including technological tools intended to prevent the development of frailty.
METHODS: Nine interviews were conducted about experiences of participating in an intervention including use of technological tools to support physical activity. Qualitative content analysis was applied.
RESULTS: Two themes revealed: (1) Perceptions of being old are seldom positive, and (2) A rewarding and fruitful participation in the project with suggestions for improvement. Becoming older was related to physical pain and tiredness reducing the performance of former meaningful activities as well as an increase in mental stress. There was also a tendency to postpone the start of everyday activities, and in general, fewer activities were planned for one day than at younger ages. Participating in a physical activity intervention, including the use of technical tools, was considered meaningful and added motivation for engaging in other physical activities, this despite some difficulties with technical tools provided by the program. The contact with health care and the research team was appreciated. In addition, contact with other participants was requested and reported to be highly valued if added to the intervention, which could have been an expression of loneliness.
CONCLUSION: Participation in a prevention program motivated activities and social interaction. Adding opportunities for participants to meet each other is suggested for improving the intervention in terms of increasing the social dimensions. Our findings conclude that despite difficulties with handling the technical tools for the home-monitoring and communication platform, participation in the POSITIVE intervention was in general a positive experience.
PURPOSE: A composition containing Psoralea corylifolia for treating prostate cancer is provided to suppress prostate cancer cell growth and to induce apoptosis. CONSTITUTION: A composition for treating prostate cancer contains Psoralea corylifolia. A composition for anti-cancer contains Psoralea corylifolia as an active ingredient and additionally contains pharmaceutically acceptable carrier or diluents. The composition is used by alternating with one or more chemotherapies. A drug is manufactured by mixing, granulating, tabletizing, or film-coating process. A liquid dispersion solution for oral administration is syrup, emulsion, or suspension.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use excellent in stability, causing no change in color, by using both a dibenzoylmethane-based compound and powder subjected to a specific surface treatment. SOLUTION: This skin preparation for external use comprises a dibenzoylmethane-based compound and powder subjected to a surface treatment with a silicone compound so as to contain >=1.25×10<-3> mol of silicon atom based on 100 m<2> powder surface area. The powder is preferably subjected to surface treatment by bringing the silicone compound in the form of vapor. The dibenzoylmethane-based compound is preferably 4-tert-butyl-4'- methoxydibenzoylmethane. The powder is preferably fine particle titanium dioxide having <=0.2 μm average particle diameter. The addition of the titanium dioxide can provide an anti-suntan cosmetic capable of effectively protecting skin from ultraviolet rays in UV-A and UV-B regions.
The invention discloses a compound medicine preparation capable of treating secondary hypertension. The compound medicine preparation is mainly prepared from the following medical ingredients in parts by weight: a mixture including 30-150 parts of metoprolol tartrate and 50-90 parts of enalapril maleate capsules. The invention provides a compound hypertension-resistant preparation which is convenient to take and safe in use and contains metoprolol tartrate and an RAS inhibitor. The compound hypertension-resistant preparation is mainly used for omnibearingly controlling systolic pressure and thus certainly achieving decrease of diastolic pressure. The compound medicine preparation is capable of not only relieving an ET vasoactive effect, but also relieving an AngII vasoactive effect, furthermore relieving pathologic blood vessel proliferative effects of ET and AngII. By aiming at currently-known main pathologic neurohumor factors of causing hypertension, the compound medicine preparation has an effect of reducing systolic pressure to the greatest extent and also bringing an effect of reducing diastolic pressure.
Methods and systems for topology-based clinical data mining are provided. An example system includes a pre-processing module to process the clinical datasets to generate a table of outcomes and a table of predictors of trial subjects. The system includes a graph construction module to generate metric graphs based on the table of outcomes. The metric graphs include nodes representing the subjects and edges selectively connecting the nodes according to pre-determined criteria. The graph construction module may select a graph of interest from the metric graphs and generate a compressed version of the graph of interest. The system may further include an interactive visualization module to display a graphical representation of the graph of interest or the compressed version, receive selection of groups of the trial subjects, automatically highlight groups of related subjects, and perform, using the table of predictors, a statistical analysis of predictors of subjects within the selected groups.
Acute disseminated encephalomyelitis (ADEM) has been identified as an Adverse Event of Special Interest in the COVID-19 vaccine programme due to its long-standing temporal association with a wide range of other vaccines. Case reports of ADEM shortly following COVID-19 vaccination have now been documented.    There were 217 ADEM admissions in 215 individuals in the period 8th December 2020 to 31st March 2023. An increased risk of ADEM following the first dose of ChAdOx1 vaccine was observed (relative incidence (RI) = 3.13, 95% Confidence Interval (CI) [1.56-6.25]) with a vaccine attributable risk of 0.39 per million doses. When doses 1 and 2 were combined this increased risk remained just significant (1.96 [95%CI 1.01-3.82]). No significant increased risk was observed with any other vaccine or dose. This small, elevated risk after the first dose of ChAdOx1-S vaccine demonstrates how large national electronic datasets can be used to identify very rare risks and provides reassurance that any risk of ADEM following the ChAdOx1-S COVID-19 vaccination is extremely small. Given the rarity of this risk, further studies in settings with access to data on large populations should be carried out to verify these findings.
This study includes two parts. Part One will evaluate two ALLN-346 formulations, a fast release and a slower sustained release. Subjects will receive a single tablet of each formulation and a capsule of each formulation at separate assessment visits. Subjects will attend a maximum of 4 assessment visits. The primary purpose of this part of the study is to understand the gastrointestinal transit time and disintegration behaviour of the formulations in vivo in normal healthy volunteers when ALLN-346 formulations are given with light meal.

Part Two will involve a second cohort of subjects and will comprise further scintigraphic studies on one or both formulation(s) from Part One in fasted and/or fed states. Subjects will attend a maximum of 4 assessment visits, the number of treatment arms will be decided following completion of Part One.